✨ Free AI Report
Athira Pharma, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Athira Pharma, Inc.
Company Research

Athira Pharma, Inc.: Business Overview, Financials & Competitive Analysis

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's ...

Analyst-debate audio for Athira Pharma, Inc.

AskCyborg analysts argue the bull and bear cases for Athira Pharma, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Challenged

Cyborg Score thesis

Early-stage neurodegenerative disease biotech at inflection point with viable pipeline but severe capital constraints and...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Athira Pharma, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Athira Pharma, Inc. Overview

Pro stress-test →

Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's drug development pipeline includes potential first-in-class and next-generation novel small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system.

Strategic Profile

Pro stress-test →

Athira is on track to enable dosing ALS patients in 2025. Athira continues to explore strategic alternatives focused on maximizing stockholder value after receiving topline results from its Phase 2/3 LIFT-AD clinical trial in September 2024. The company faces resource constraints and has undertaken significant cost restructuring.

Competitive Landscape

Pro stress-test →

Cassava Sciences, Cognition Therapeutics, Quince Therapeutics, Alzheon, and Neuphoria Therapeutics are among 15 competitors in the neurodegenerative disease drug development space. Athira competes in a crowded market with limited resources relative to better-capitalized rivals.

Industry Context

Athira Pharma, Inc. operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus.

Key facts

Founded: 2011 · Headquarters: Bothell, WA · Employees: 26 · Market cap: $16.5M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Athira Pharma, Inc..

  • ATH-1105 demonstrated a favorable safety profile and was well-tolerated in healthy volunteers, supporting continued clinical development.
  • Cash position declined from $51.3M (end of 2024) to $25.2M (September 30, 2025), with Q3 2025 showing reduced quarterly burn rate.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • December 2025Announced exclusive license to Lasofoxifene Phase 3 development program for metastatic breast cancer and financing for up to $236 million
  • November 2025Completed Phase 1 clinical study of ATH-1105 in healthy volunteers with favorable safety profile
  • +2 moreTrack every material event for Athira Pharma, Inc. as it happens. Explore monitoring →
Get alerted when Athira Pharma, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cassava SciencesAlzheimer's disease therapeutics→Cognition TherapeuticsNeurodegenerative disease treatments→Quince TherapeuticsNeurodegenerative disease focus→

Compare Athira Pharma, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Athira Pharma, Inc. operates in Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Drug Discovery - Neurodegenerative Disease Focus research →
NEW · MCP server

Ask your AI assistant about Athira Pharma, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Athira Pharma, Inc. and its top competitor on Cyborg Score”
“What did Athira Pharma, Inc. do this quarter?”
“Is Athira Pharma, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Athira Pharma, Inc. do?+
Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's ...
What is Athira Pharma, Inc.'s Cyborg Score?+
Athira Pharma, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Athira Pharma, Inc.'s main competitors?+
Named competitors include Cassava Sciences, Cognition Therapeutics, Quince Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Athira Pharma, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Athira Pharma, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Athira Pharma, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score